0001104659-24-035104.txt : 20240315
0001104659-24-035104.hdr.sgml : 20240315
20240315183908
ACCESSION NUMBER: 0001104659-24-035104
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240313
FILED AS OF DATE: 20240315
DATE AS OF CHANGE: 20240315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bhatt Padmanabh P.
CENTRAL INDEX KEY: 0001539215
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35518
FILM NUMBER: 24756419
MAIL ADDRESS:
STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC.
STREET 2: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001356576
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-838-2500
MAIL ADDRESS:
STREET 1: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060317
4
1
tm248954-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-03-13
0
0001356576
SUPERNUS PHARMACEUTICALS, INC.
SUPN
0001539215
Bhatt Padmanabh P.
C/O SUPERNUS PHARMACEUTICALS, INC.,
9715 KEY WEST AVENUE
ROCKVILLE
MD
20850
0
1
0
0
Sr. VP of IP, CSO
1
Common Stock
2024-03-13
4
M
0
26250
23.99
A
34820
D
Common Stock
2024-03-13
4
S
0
26250
34.10
D
8570
D
Common Stock
2024-03-13
4
M
0
36116
12.98
A
44686
D
Common Stock
2024-03-13
4
S
0
36116
33.48
D
8570
D
Employee Stock Option (Right to Buy)
12.98
2024-03-13
4
M
0
36116
0
D
2026-03-01
Common Stock
36116
0
D
Employee Stock Option (Right to Buy)
23.99
2024-03-13
4
M
0
26250
0
D
2030-02-21
Common Stock
26250
8750
D
Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.99 to $34.28. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.98 to $33.74. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The option vested in four equal annual installments beginning on March 1, 2017.
The option vested in four equal annual installments beginning on February 21, 2021.
/s/ Timothy C. Dec, as attorney-in-fact
2024-03-15